**Core Concept:** Mooren's ulcer is a rare and aggressive form of ulcerative keratitis, characterized by progressive peripheral ulceration and peripheral corneal thinning. It is associated with autoimmune disorders, specifically collagen vascular diseases like systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome.

**Why the Correct Answer is Right:** The correct answer is "topical corticosteroids and cyclosporine." Mooren's ulcer treatment aims to suppress the inflammatory response and promote healing. Topical corticosteroids help reduce inflammation and prevent further ulceration, while cyclosporine acts as an immunosuppressive agent, reducing the immune system's attack on the cornea. Combining these two agents enhances their therapeutic effect and minimizes the risk of systemic side effects associated with oral corticosteroids.

**Why Each Wrong Option is Incorrect:**

A. **Topical antibiotics:** Although antibiotics are used in bacterial keratitis, they are not effective in Mooren's ulcer due to the primary involvement of the immune system and the absence of bacterial infection.

B. **Systemic corticosteroids:** Systemic corticosteroids are more potent than topical corticosteroids but carry significant systemic side effects, making them less suitable for Mooren's ulcer treatment.

C. **Topical cyclosporine:** While topical cyclosporine has some anti-inflammatory effect, its therapeutic effect is significantly less than oral cyclosporine, and its combination with topical corticosteroids is not commonly used due to the risk of ocular hypertension and cataract formation.

D. **Topical cyclosporine and topical corticosteroids:** This combination is used because both agents have synergistic effect, enhancing their therapeutic effect and minimizing the systemic side effects of oral cyclosporine.

**Clinical Pearl:** Mooren's ulcer is a challenging condition to manage, and treatment should be tailored to the individual patient's condition. In severe cases, oral cyclosporine in combination with systemic corticosteroids may be considered, but the risk-benefit ratio must be carefully evaluated. In most cases, a combination of topical corticosteroids and cyclosporine is used to balance the therapeutic effect and minimize systemic side effects.